General
Lupin Neurosciences is committed to working with Healthcare Professionals to develop science-based solutions that stretch beyond access to lifechanging treatment options to optimize patient care in underserved neurological diseases.
2025 MDF: 2025 Myotonic Dystrophy Foundation Congress, Indianapolis, USA, 2-4 May 2025
Pharmacokinetics
Pharmacokinetics Profile of NaMuscla® Prolonged Release QD is comparable to NaMuscla® Immediate Release TD
Sajeev Chandran, Anirudha Kute, Makarand Avachat, Russell Brierley, Nikki Adetoro, Alla Zozulya-Weidenfeller